免疫学
A trusted leader dedicated to transforming the lives of people with immune-mediated diseases, today and tomorrow.\r\n"}}" id="text-80886a1410" class="cmp-text">
受信任的领导人致力于改变人们的生活与免疫介导性疾病,今天和明天。
提高标准
With each new discovery, we create a better understanding of how patients are different — even those diagnosed with the same disease — so we can develop more personalized approaches to immunological diseases. More than 1 million people with immune-mediated diseases worldwide are treated with our therapies.\r\n"}}" id="text-d5ad066521" class="cmp-text">
与每一个新发现,我们创建一个更好的理解病人是不同的——即使是那些患有相同疾病——所以我们可以开发更多个性化的免疫性疾病的方法。全世界有超过100万的免疫介导性疾病患者接受治疗。
在马萨诸塞州的科学家AbbVie生物学研究中心专注于创新的解决方案的一些医学最艰巨的挑战,包括免疫学。
研究兴趣
We’re building on our deep expertise and historic legacy in immunology research to explore new disease areas, create a more patient-centric discovery and development process, and offer solutions for more diverse patient populations. Our advanced technologies support a rich pipeline of medicines for some of the most challenging immunological diseases. Research interests include:\r\n
Understanding drivers of disease
\r\nIncreasing understanding of disease through molecular profiling of patient samples, exploring preclinical disease to post-treatment states and using multi-omics, machine learning and artificial intelligence.
\r\n
\r\n Fit for purpose drug discovery
\r\nRedesigning drug discovery using molecular profiles that reveal the genetic makeup of disease rather than diagnoses that describe disease.
\r\n
\r\nIncreasing probability of success in drug discovery
\r\nDeveloping more humanized preclinical model systems (e.g., CRISPR, iPSC, organoids and disease-on-a-chip) and state-of-the-art immunological, imaging and computational approaches to drive innovation of target identification, validation, benchmarking and prioritization.
\r\n
\r\nInducing of immune tolerance
\r\nPursuing the biology behind inducing tolerance rather than suppressing pathological immune activity.
\r\n
\r\nDrug delivery platforms
\r\nInvesting in targeted drug delivery platforms, which are designed to specifically deliver a potent drug to the right cells and/or tissues. These include bispecifics, Antibody-Drug Conjugate platforms, small molecule approaches, RNA therapeutics and in situ cell reprogramming.
我们建立在深厚专业知识和历史遗留在免疫学研究探索新的疾病领域,创建一个更成规发现和开发过程,并提供解决方案更为多样化的患者群体。狗万正网地址我们的先进技术支持丰富的药物管道的一些最具有挑战性的免疫性疾病。研究兴趣包括:
了解疾病的司机
增加理解疾病的患者样本的分子分析,探索临床疾病治疗后的状态和使用multi-omics,机器学习和人工智能。
适合目的药物发现
重新设计药物发现使用分子资料揭示疾病的基因构成,而不是描述疾病的诊断。
在药物发现增加成功的可能性
开发更多人性化的临床前模型系统(例如,CRISPR, iPSC,瀑样和disease-on-a-chip)和先进的免疫,成像和计算方法来推动创新的目标识别,验证、基准和优先级。
诱导的免疫耐受
追求背后的生物诱导宽容而不是抑制病理免疫活动。
药物输送平台
投资于靶向药物输送平台,旨在专门提供一个强有力的药物对细胞和/或组织。这些包括双特异性抗体药物共轭平台、小分子方法,RNA治疗原位细胞重新编程。
合作伙伴关系
Strategic collaborations bring together the brightest minds in immunology working to bring more options to patients, faster. We join forces with partners that complement our strengths, capabilities and commitment to people with immune-mediated diseases.\r\n"}}" id="text-a9cc37d022" class="cmp-text">
战略合作汇集免疫学中最亮的思想工作,给病人带来更多选择,更快。我们与合作伙伴联手,补充我们的优势,功能和免疫介导性疾病患者的承诺。
精密医学
Innovation in this area helps researchers understand complex immune-mediated diseases, from how a person’s genetics affect disease to leveraging clinical trial data to deliver personalized medicine. Advanced technologies like molecular profiling and biomarker analyses allow us to dig even deeper.\r\n"}}" id="text-ae932017f5" class="cmp-text">
创新在这一领域可以帮助研究人员了解复杂的免疫介导性疾病,从一个人的基因是如何影响疾病提供个性化医疗利用临床试验数据。先进的技术如分子分析和生物标志物分析让我们更深的挖掘。
投资组合的心态
We have nearly a quarter-century of experience in immune-mediated disease, and we’re not stopping. We continue to investigate diseases with critical unmet diseases, building robust development programs that advance how the disease is treated.\r\n"}}" id="text-d3c6465406" class="cmp-text">
我们已经在免疫介导性疾病近25年的经验,我们不停止。我们继续探讨疾病与关键的未满足的疾病,构建健壮的发展规划,推进对该疾病的治疗。狗万正网地址
对快节奏的事业在科学感兴趣吗?
Help us create the future of medicine. \r\n"}}" id="text-81bd2befaa" class="cmp-text">
帮助我们创造未来。
病人的故事
外部链接
Unless otherwise specified, all product names appearing in this internet site are trademarks owned by or licensed to AbbVie Inc., its subsidiaries or affiliates. No use of any AbbVie trademark, trade name, or trade dress in this site may be made without the prior written authorization of AbbVie Inc., except to identify the product or services of the company.\r\n
Copyright © 2023 AbbVie Inc. North Chicago, Illinois, U.S.A.
\r\n"}}" id="text-72289d7192" class="cmp-text">除非另有规定,所有产品名称出现在本网站商标或许可AbbVie Inc .旗下的子公司或分支机构。没有使用任何AbbVie商标,商号,或贸易服装在这个网站可能没有AbbVie Inc .的事先书面授权,除了确定公司的产品或服务。
版权©2023 AbbVie Inc .北芝加哥,伊利诺斯州,美国
